

The ERICs in Horizon Europe

A successful case



www.eric-forum.eu



The ERIC Forum is supported by ERIC Forum 2 project, funded by the European Union under grant agreement n°101124559

On the ERICs and the ERIC Forum

The European Research Infrastructure Consortium (ERIC) is a specific legal form that facilitates the establishment and operation of Research Infrastructures with European interest.

The ERIC model

It provides a legal capacity recognised in all EU Member States, a faster process to create an international organisation, and exemptions from VAT and excise duty. This makes the ERIC model a fundamental tool for the establishment and operation of common research infrastructures.

The ERIC Forum

The ERIC Forum strategically contributes to the development of ERIC related policies by sharing best practices, tackling common challenges, fostering visibility, impact and sustainability of ERICs and contributing to the European science policies and research context.

With 32 ERICs established, the ERIC Forum has become one of the leading voices in European science policy.

ADVANTAGES OF BEING AN ERIC



A legal capacity recognized in all EU Member States



Flexibility to adapt to specific requirements of each infrastructure



A faster process than creating an international organisation



Exemptions from VAT and excise duty


Advantages for Research

ERICs provide the European research community with access to high-quality data and cutting-edge technologies to support scientific excellence and respond to global challenges.

Moreover, they support mobility of researchers and knowledge across the ERA, promote collaboration between countries and favour a European coordination of national infrastructure capacities and capabilities.

More in details

ACCESS TO RIs



- Provide access to state-of-the-art research facilities and services for researchers from Europe and beyond, including universities, industries, SMEs, and incubators.
- Experts provide technical and scientific support to users accessing the RIs.
- ERICs offer predefined access processes, ensuring efficient and transparent use of resources.
- Researchers can access facilities either through funded projects (free access) or with their own funds (subject to capacity).

DEVELOPMENT & SERVICES



- Potential upscaling of research from TRL1 to higher TRLs (e.g. TRL7,8,9) in several research infrastructures facilities.
- Direct contribution to technological development.
- Promote the mobility of researchers and knowledge across the European Research Area, fostering international collaboration.

ECRIN-ERIC

<https://ecrin.org/>

ECRIN facilitates multinational clinical research in Europe, by providing expert advice, services and tools for the set-up and management of investigator or SME-led clinical studies. It connects national networks of clinical trial units across Europe, with the vision of generating high-quality scientific evidence to optimise medical practice.

SERVICES

Clinical Trials Services: ECRIN provides end-to-end clinical operations support to academic researchers and SMEs, with focus on multinational clinical trials.

Clinical Research Tools: ECRIN develops, contributes to, and maintains a suite of freely accessible tools designed to support high-quality clinical research.

Data Centre Certification: ECRIN audits European non-commercial data centres to assess their ability to deliver high-quality data management services for controlled clinical trials.

Training and capacity building: ECRIN offers targeted training courses and webinars for researchers and other clinical research stakeholders. Training focuses on the design and coordination of multinational clinical trials and addresses practical challenges such as cross-border research and sensitive data sharing.

HORIZON EUROPE - FUNDING

Pillar I



Pillar II



ERA4HEALTH – A SUCCESSFUL CASE

<https://era4health.eu/>

This Partnership brings the opportunity to strengthen European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European public health needs. ERA4Health aims to deliver influential contributions and a sustainable model of funding for ground-breaking translational research in the health domain across Europe and beyond. Within the Partnership, ECRIN:

- Contributed to the supplementation of the Strategic Research and Innovation agenda to include investigator initiated clinical studies (IICS)
- Developed a framework enabling the launch of IICS calls, including a dedicated funding mechanism, specific eligibility criteria and tailored selection and monitoring procedures
- Mapped IICS funding sources and organisations supporting clinical IICS in Europe
- Produced training material, a clinical trial agreement template for multinational clinical studies, as well as recommendation booklets and guidelines to support the planning and conduct of clinical trials, with a focus on innovative methodologies such as master protocol designs, trials within cohorts (TWiCs), decentralised trials, and data sharing.

GENERAL INFORMATION

Acronym: ERA4Health
Grant Agreement Number: 101095426
Funded under PROGRAMME: HORIZON.2.1 - Health
Starting date: 01/11/2022
Ending date: 31/10/29

PROJECT PARTNERSHIP

The ERA4Health Partnership, a broad network of 48 partners from 26 countries, brings together a diverse network of research funders, ministries, agencies, research institutes and foundations from across Europe and beyond to support collaborative health research. Partners by country: AT (BMBWF, FW), BE (EV ILVO, FRS-FNRS, FWO, KCE), CZ (MZCR), DE (DLR, BMFTR), DK (IFD), EE (ETAG), EG (ASRT), ES (ISCIII, AEI, FICYT, CSCJA, SEKUENS, DS-CAT), FR (ANR, ECRIN, Fr-MoH, ETPN), GR (GSRI), HU (NKFIH), IE (HRB), IL (CSO-MOH), IT (IT-MOH, MUR, FRRB), LT (LMT), LV (LCS), NL (NWO, ZonMw, EATRIS), NO (RCN, HSØRHF), PL (NCBR), PT (AICIB, FCT), RO (UEFISCDI), SK (SAS, BMC-SAS, SCSTI), SE (SRC), TR (TUBITAK, TÜSEB), UK (DHSC), US (BT1D).

LIVERRATION – A SUCCESSFUL CASE

<https://liveration.eu/>

LIVERRATION aims to conduct an ambitious, pragmatic multicenter clinical trial in patients with colorectal cancer liver metastasis and liver cancer at 20 clinical centres in 7 different countries to determine whether additional ablated margin produced by radiofrequency can decrease the recurrence rate and improve patient survival. In close contact with patient associations, LIVERRATION will also evaluate patients' quality of life and their experiences throughout the process of the intervention and its comparison with other therapeutic alternatives in terms of quality of life and patient experience in real-world settings.

Within this project, ECRIN works very closely with the sponsor and provides operational trial management across borders including the overall coordination of the trial, regulatory and ethical submissions, monitoring, data-management and vigilance.

GENERAL INFORMATION

Acronym: LIVERRATION

Grant Agreement Number: 101104360

Funded under PROGRAMME: HORIZON.2.1 – Health

Starting date: 01/06/2023

Ending date: 31/05/28

PROJECT PARTNERSHIP

The LIVERRATION consortium is composed of 8 research groups, 4 affiliated entities and 20 clinical sites. A multidisciplinary team of internationally recognised research groups, experts in the field of colorectal cancer liver metastasis and patient-centered care, and leading companies supporting the effective development of this Research and Innovation Action. Partners by country: ES (IMIM, VECMEDICAL, SACSIS, FAD, SERMAS, FIBHULP, FIMABIS, FIMIM, Hospital del Mar, Valencia Clinical Hospital, Hospital Sanchinarro, Reina Sofía Hospital, Girona Hospital), BE (ELPA), GR (UOI, Athens National and Kapodistrian University), FR (ECRIN, INSERM, Beaujon Hospital, Paul Brousse Hospital, Strasbourg Hospital), IT (Tor Vergata Hospital, San Raffaele Hospital, Miulli Hospital, Napoli Cancer Institute, San Camillo Forlanini), PT (SHINE), SI (University Hospital Ljubljana), PL (University Hospital Zielona Góra, Norbert Barlicki Memorial University Hospital No. 1, Medical University of Warsaw, Mielecki Hospital of the Medical University of Silesia CH (Winterthur Hospital), NL (Eurotransplant, often cited under Netherlands institutions).